Literature DB >> 23830224

Nasopharyngeal carcinoma in children and adolescents in an endemic area: a report of 185 cases.

Zheng Yan1, Liangping Xia, Yuanyuan Huang, Ping Chen, Li Jiang, Bei Zhang.   

Abstract

BACKGROUND: This study aimed to demonstrate the clinical and therapeutic features of nasopharyngeal carcinoma (NPC) in children and adolescents in Southern China, an endemic area. PATIENTS AND METHODS: A total of 185 newly diagnosed NPC patients younger than 21 years old in the Sun Yat-sen University Cancer Center from 1993 to 2011 were retrospectively analyzed. Overall survival (OS) rate estimates and Kaplan-Meier survival curves were calculated. Cox proportional hazard ratios (HRs) were used to identify independent prognostic factors for survival. Chi-square test was used to compare the incidence of sequelae and the stage distribution between different subgroups.
RESULTS: Most patients were male (71.4%). The main presenting symptoms were neck mass (44.9%), tinnitus/hearing loss (36.2%), bloody nasal discharge (22.7%), headache (22.2%), and nasal obstruction (20.0%). Stage I, II, III, and IV patients accounted for 1.1%, 8.1%, 43.8%, and 47.0%, respectively, of the total number of patients included in the study. All patients were treated by radiotherapy: 39 Gy-84 Gy to primary tumors (median, 68 Gy) and 36 Gy-74 Gy to cervical lymph nodes (median, 60 Gy); 84.3% of the patients were treated by chemotherapy either. The complete response rate was 94.1%. The 5-, 10-, and 15-year survival rates were 78% ± 4%, 70% ± 5%, and 66% ± 6%, respectively. Tumor node metastasis (TNM) stage was the statistically significant predictor of distal metastasis and OS. Distal metastasis was the major pattern of treatment failure. The main long-term complications of therapy were xerostomia (47.0%), hearing loss (28.1%), neck fibrosis (24.3%), trismus (12.4%), glossolalia (7.0%), and radiation encephalopathy (5.4%). The incidences of these morbidities were significantly higher in the high radiation dose (more than the median) group than in the low radiation dose group (less than or equal to the median), while no differences in survival were observed.
CONCLUSIONS: In spite of the majority of patients diagnosed at the advanced stage, children and adolescents with NPC had excellent survival except metastatic disease. The TNM stage was the most relevant prognostic factor. A higher radiation dose (>68 Gy) could not improve survival but could increase long-term morbidities.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Children and adolescents; Morbidity; Nasopharyngeal carcinoma; Radiotherapy; Survival

Mesh:

Year:  2013        PMID: 23830224     DOI: 10.1016/j.ijporl.2013.06.005

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  9 in total

1.  NSUN2 Promotes Tumor Progression and Regulates Immune Infiltration in Nasopharyngeal Carcinoma.

Authors:  Xinya Tong; Yilan Xiang; Yuanbo Hu; Yingying Hu; He Li; Huilin Wang; Kong-Nan Zhao; Xiangyang Xue; Shanli Zhu
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

Review 2.  Prognostic aspects in the treatment of juvenile nasopharyngeal carcinoma: a systematic review.

Authors:  Federico Maria Gioacchini; Michele Tulli; Shaniko Kaleci; Giuseppe Magliulo; Massimo Re
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-18       Impact factor: 2.503

3.  Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience.

Authors:  Anaïs Jouin; Sylvie Helfre; Stéphanie Bolle; Line Claude; Anne Laprie; Emilie Bogart; Céline Vigneron; Hélène Potet; Anne Ducassou; Audrey Claren; François Georges Riet; Marie Pierre Castex; Cécile Faure-Conter; Brice Fresneau; Anne Sophie Defachelles; Daniel Orbach
Journal:  Strahlenther Onkol       Date:  2019-04-08       Impact factor: 3.621

4.  Nasopharyngeal carcinoma in children and adolescents - a single institution experience of 158 patients.

Authors:  Weixin Liu; Yuan Tang; Li Gao; Xiaodong Huang; Jingwei Luo; Shiping Zhang; Kai Wang; Yuan Qu; Jianping Xiao; Guozhen Xu; Junlin Yi
Journal:  Radiat Oncol       Date:  2014-12-05       Impact factor: 3.481

5.  The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA.

Authors:  Ya-Nan Jin; Ji-Jin Yao; Si-Yang Wang; Wang-Jian Zhang; Fan Zhang; Guan-Qun Zhou; Zhi-Bin Cheng; Hao-Yuan Mo; Ying Sun
Journal:  Transl Oncol       Date:  2017-05-29       Impact factor: 4.243

6.  Exploring the Optimal Chemotherapy Strategy for Locoregionally Advanced Children and Adolescent Nasopharyngeal Carcinoma Based on Pretreatment Epstein-Barr Virus DNA Level in the Era of Intensity Modulated Radiotherapy.

Authors:  Ziyi Zeng; Chen Chen; Lanlan Guo; Cheng Zhang; Lei Chen; Chuanping Yuan; Lixia Lu
Journal:  Front Oncol       Date:  2021-01-07       Impact factor: 6.244

7.  [Therapeutic outcomes of nasopharyngeal carcinomas: a single-center study conducted at the Fattouma Bourguiba University Hospital in Monastir, Tunisia].

Authors:  Amel El Korbi; Sarra Ben Tkhayat; Rachida Bouatay; Mehdi Ferjaoui; Naourez Kolsi; Khaled Harrathi; Jamel Koubaa
Journal:  Pan Afr Med J       Date:  2021-02-09

8.  Retrospective analysis of clinical features and prognosis of nasopharyngeal carcinoma in children and adolescents.

Authors:  Tianyu Gong; Yupeng Liu; Huiqun Jie; Min Liang; Wenjin Wu; Jingrong Lu
Journal:  Front Pediatr       Date:  2022-09-16       Impact factor: 3.569

9.  Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.

Authors:  Yang Li; Lin-Quan Tang; Li-Ting Liu; Shan-Shan Guo; Yu-Jing Liang; Xue-Song Sun; Qing-Nan Tang; Jin-Xin Bei; Jing Tan; Shuai Chen; Jun Ma; Chong Zhao; Qiu-Yan Chen; Hai-Qiang Mai
Journal:  Cancer Res Treat       Date:  2018-01-08       Impact factor: 4.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.